InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,599.14
(
-1.20%
)
US TECH 100
19,349.60
(
-2.54%
)
Dow Jones
41,170.52
(
0.53%
)
Brent Oil
84.41
(
1.31%
)
Bitcoin
64,688.43
(
-0.62%
)
Post# of 77519
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

croptop

Send PM Follow Ignore
Followers 20
Posts 2975
Boards Moderated 0
Alias Born 03/13/2013

croptop

Re: Frankinjohn74 post# 63922

Thursday, 09/19/2013 7:22:08 PM

Thursday, September 19, 2013 7:22:08 PM

Post# of 77519
Hmmmmm
Was Europe ahead of USA?
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2013/03/human_orphan_001170.jsp&mid=WC0b01ac058001d12b

On 24 January 2013, orphan designation (EU/3/12/1097) was granted by the European Commission to Celgene Europe Limited, United Kingdom, for lenalidomide for the treatment of follicular lymphoma.



Great for Celgene!!!

MMRF is not a love child.. No such thing as "loyalty" to a stock, a CEO, or a Company, especially a OTC, its an investment, and only good for a return of $$$$....Keep real
JMHO

If anyone believes this post contains anything false, tortious or libelous, please point it out. I will promptly retract it and apologize or else explain why I believe you are wrong.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up